Medi-Cal Rx sets 340B billing rules for drugs under HRSA's revised Rebate Model Pilot starting January 1, 2027
Published November 15, 2026 · Coverage November 8–14, 2026, Pacific · Medium priority
On November 1, 2026, Medi-Cal Rx issued an alert on the Health Resources and Services Administration (HRSA) 340B Rebate Model Pilot Program. HRSA announced a revised Pilot on July 31, 2026, with approved rebate plans scheduled to take effect January 1, 2027; participating manufacturers may provide the 340B ceiling price through a post-purchase rebate instead of an upfront discount. From January 1, 2027, pharmacy providers may submit Medi-Cal Rx 340B claims for Pilot drugs using the 340B ceiling price in effect on the date of service plus the professional dispensing fee, and must reverse and resubmit claims when the net actual acquisition cost after the rebate differs.

Background
The revised Pilot follows the 2026 Pilot, whose implementation was suspended after federal litigation, according to the alert. California law requires Medi-Cal 340B claims to be billed at no more than the covered entity's actual acquisition cost plus the dispensing fee.
Who this affects
Hospitals and other 340B covered entities whose pharmacies bill Medi-Cal Rx for outpatient drugs, and their pharmacy, 340B program and revenue cycle teams.
Why it matters
Inference: for Pilot drugs, the price paid upfront may be higher than the 340B price until the manufacturer rebate arrives, so a claim billed at the ceiling price may later need correcting. Inference: pharmacies will need to track rebates by claim; the alert says a claim can be rebilled up to 12 months from the date of service with appropriate documentation.
Required actions
- From January 1, 2027, pharmacy providers in the 340B program that bill Medi-Cal Rx for Pilot drugs at the 340B ceiling price must submit the initial claim at the ceiling price plus the professional dispensing fee in effect on the date of service.
- After the manufacturer rebate is received, they must reverse and resubmit the claim at the correct net actual acquisition cost, or at the non-340B price if the rebate was denied, when the net cost differs from the ceiling price billed. If the net actual acquisition cost after receipt of the rebate is a negative amount, providers should bill $0.01 as the claim's ingredient cost, plus the applicable professional dispensing fee.
Recommended action
- Have 340B and pharmacy teams identify which manufacturers have approved Pilot rebate plans and which Medi-Cal Rx claims will involve those drugs.
- Set up a process to match manufacturer rebates to Medi-Cal Rx claims and rebill within the 12-month window, keeping the documentation the alert says audits may request.
Implementation playbook
- Identify which manufacturers have approved Pilot rebate plans and which Medi-Cal Rx claims will involve their drugs. Owner: 340B Program. Due: 2026-12-15.
- Configure Medi-Cal Rx claims for Pilot drugs at the 340B ceiling price plus the professional dispensing fee in effect on the date of service, from January 1, 2027. Owner: Pharmacy and Revenue Cycle. Due: 2026-12-31.
- Set up rebate-to-claim matching so claims are reversed and resubmitted at the net actual acquisition cost (when that cost is negative, a $0.01 ingredient cost plus the applicable professional dispensing fee), or at the non-340B price if a rebate is denied, within 12 months of the date of service, and keep the documentation audits may request. Owner: 340B Program and Revenue Cycle. Due: 2027-01-31.
Scope and timing
- Authority status
- Guidance
- Responsible owner
- Pharmacy; 340B Program; Revenue Cycle
- Publication date
- 2026-11-01
- Effective date
- 2027-01-01 (start of the billing rules for drugs under the revised Rebate Model Pilot)
- Other dates
- HRSA announced the revised Pilot on July 31, 2026, as the alert reports.
Not established
HRSA's July 31, 2026 announcement and the Pilot page were not read; which manufacturers have approved rebate plans is not established. The litigation status is as the alert reports it.
Sources
Complete edition and supplemental material
This article in the complete report →
Executive triage, source-coverage limitations, context and forward horizons remain in the complete report.
Read the entire Medicare & Medicaid Sweep report →